Edetate disodium anhydrous API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Edetate disodium anhydrous API 139-33-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Edetate disodium anhydrous. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Edetate disodium anhydrous
- Synonyms:
- Anhydrous disodium edetate , Disodium EDTA, anhydrous , Edetate disodium, anhydrous , EDTA disodium salt (anhydrous)
- Cas Number:
- 139-33-3
- DrugBank number:
- DB14600
- Unique Ingredient Identifier:
- 8NLQ36F6MM
General Description:
Edetate disodium anhydrous, identified by CAS number 139-33-3, is a notable compound with significant therapeutic applications. Edetate disodium anhydrous is a polyvalent chelating agent used to treat hypercalcemia and digitalis toxicity associated ventricular arrhythmias.
Indications:
This drug is primarily indicated for: Edetate disodium is indicated for emergency treatment of hypercalcemia and digitalis toxicity associated ventricular arrhythmias. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Edetate disodium anhydrous undergoes metabolic processing primarily in: Edetate is almost completely unmetabolized _in vivo_. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Route of Elimination:
The elimination of Edetate disodium anhydrous from the body primarily occurs through: After intravenous administration, 95% of the dose is recovered in the urine after 24 hours. Oral administration in rats leads to 5.3% recovery in urine and 88.5% recovery in feces. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Edetate disodium anhydrous is distributed throughout the body with a volume of distribution of: Data regarding the volume of distribution of edetate disodium anhydrous is not readily available. This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Edetate disodium anhydrous is a critical factor in determining its safe and effective dosage: The mean clearance of edetate in 1 month olds is 54.6mL/min/1.73m2. 2-17 year olds have a mean clearance of 113.9 ± 24.4 mL/min/1.73m2. It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Edetate disodium anhydrous exerts its therapeutic effects through: Edetate disodium anhydrous is a polyvalent ion chelator that reduces blood concentrations of calcium or digitalis. It has a long duration of action as patients are generally given 1 daily dose. The therapeutic index is wide, as high doses are generally well tolerated. Patients should be counselled regarding the risk of postural hypotension, effects of myocardial contractility, hypokalemia, hypomagnesemia, and hypoglycemia. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Edetate disodium anhydrous functions by: Edetate disodium anhydrous chelates divalent and trivalent ions such as magnesium, zinc, and calcium. The chelate is excreted in the urine, reducing concentrations of these ions in the blood. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Edetate disodium anhydrous belongs to the class of organic compounds known as tetracarboxylic acids and derivatives. These are carboxylic acids containing exactly four carboxyl groups, classified under the direct parent group Tetracarboxylic acids and derivatives. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Carboxylic acids and derivatives class, specifically within the Tetracarboxylic acids and derivatives subclass.
Categories:
Edetate disodium anhydrous is categorized under the following therapeutic classes: Calcium Binder, Calcium Chelating Activity, Calcium Chelating Agents, Chelating Activity, Chelating Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Iron Chelating Agents, Metal Chelator. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Edetate disodium anhydrous include:
- Melting Point: 240
- Boiling Point: 252
Edetate disodium anhydrous is a type of Enzyme Replacements/modifiers
Enzyme replacements/modifiers are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various enzyme-related disorders. Enzymes play a vital role in the normal functioning of the body by catalyzing specific biochemical reactions. However, in certain medical conditions, the body may lack or produce dysfunctional enzymes, leading to serious health complications.
Enzyme replacement therapy (ERT) involves administering exogenous enzymes to compensate for the enzyme deficiency in patients. These enzymes are typically derived from natural sources or produced using recombinant DNA technology. By introducing these enzymes into the body, they can effectively substitute the missing or defective enzymes, thereby restoring normal metabolic processes.
On the other hand, enzyme modifiers are API substances that regulate the activity of specific enzymes within the body. These modifiers can either enhance or inhibit the enzyme's function, depending on the therapeutic objective. By modulating enzyme activity, these APIs can restore the balance of enzymatic reactions, leading to improved physiological outcomes.
Enzyme replacements/modifiers have shown remarkable success in treating various genetic disorders, such as Gaucher disease, Fabry disease, and lysosomal storage disorders. Additionally, they have demonstrated potential in managing enzyme deficiencies associated with rare diseases and certain types of cancer.
The development and production of enzyme replacements/modifiers involve rigorous research, formulation optimization, and adherence to stringent quality control measures. Pharmaceutical companies invest substantial resources in developing these APIs to ensure their safety, efficacy, and compliance with regulatory standards.
Overall, enzyme replacements/modifiers represent a vital therapeutic category in modern medicine, offering hope and improved quality of life for patients with enzyme-related disorders.
